- Home
- PIM vs YMAB Comparison
PIM vs YMAB Comparison
Compare PIM & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIM
- YMAB
- Stock Information
- Founded
- PIM 1988
- YMAB 2015
- Country
- PIM United States
- YMAB United States
- Employees
- PIM N/A
- YMAB N/A
- Industry
- PIM Finance Companies
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PIM Finance
- YMAB Health Care
- Exchange
- PIM Nasdaq
- YMAB Nasdaq
- Market Cap
- PIM 161.4M
- YMAB 192.4M
- IPO Year
- PIM N/A
- YMAB 2018
- Fundamental
- Price
- PIM $3.33
- YMAB $4.36
- Analyst Decision
- PIM
- YMAB Buy
- Analyst Count
- PIM 0
- YMAB 11
- Target Price
- PIM N/A
- YMAB $17.55
- AVG Volume (30 Days)
- PIM 57.5K
- YMAB 202.0K
- Earning Date
- PIM 01-01-0001
- YMAB 08-11-2025
- Dividend Yield
- PIM 8.28%
- YMAB N/A
- EPS Growth
- PIM N/A
- YMAB N/A
- EPS
- PIM 0.05
- YMAB N/A
- Revenue
- PIM N/A
- YMAB $88,658,000.00
- Revenue This Year
- PIM N/A
- YMAB N/A
- Revenue Next Year
- PIM N/A
- YMAB $15.15
- P/E Ratio
- PIM $63.80
- YMAB N/A
- Revenue Growth
- PIM N/A
- YMAB 4.92
- 52 Week Low
- PIM $2.90
- YMAB $3.55
- 52 Week High
- PIM $3.28
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- PIM 51.79
- YMAB 45.29
- Support Level
- PIM $3.34
- YMAB $4.10
- Resistance Level
- PIM $3.35
- YMAB $4.62
- Average True Range (ATR)
- PIM 0.03
- YMAB 0.29
- MACD
- PIM 0.00
- YMAB -0.04
- Stochastic Oscillator
- PIM 63.64
- YMAB 20.73
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.